Trials / Completed
CompletedNCT03064438
Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
A RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PROOF-OF CONCEPT STUDY OF THE SAFETY AND EFFICACY OF ACU-D1 OINTMENT IN SUBJECTS WITH ACNE ROSACEA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Accuitis, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACCU-D1 | ACCU-D1 |
| DRUG | Vehicle | Placebo Comparator |
Timeline
- Start date
- 2017-11-28
- Primary completion
- 2018-06-05
- Completion
- 2018-06-18
- First posted
- 2017-02-27
- Last updated
- 2021-08-23
- Results posted
- 2021-08-23
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03064438. Inclusion in this directory is not an endorsement.